米国の神経血管塞栓装置市場の評価：製品別、疾患病理別、エンドユーザー別、地域別、機会、機会および予測、2018～2032年

米国ではヘルスケアサービスへのアクセス向上と保険適用により、神経血管患者の治療インフラがより強固なものとなっています。米国の神経血管塞栓装置市場は、2024年には3億8,620万米ドルと評価され、2025年から2032年にかけてCAGR 8.51％で成長すると予測されています。脳動脈における出血や異常の有病率の増加、脳動脈瘤の症例の増加、座りがちなライフスタイルによる動静脈奇形（AVM）が、神経血管塞栓装置の需要急増の主な原因です。また、米国の神経血管塞栓装置市場の成長を促進する要因としては、老年人口の増加、高血圧患者の増加、新しい神経血管塞栓装置のイントロダクションなどが挙げられます。

神経血管塞栓装置と呼ばれる血管内インプラントは、脳動脈瘤や動静脈奇形への血液供給を恒久的に遮断するように設計されています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 米国の神経血管塞栓装置市場の展望、2018年～2032年

• 市場規模と予測
  • 金額別
  • 数量別
• 市場シェアと予測
  • 製品別
    • 動脈瘤クリップ
    • 液体塞栓システム
    • 塞栓コイル
    • 血流転換ステント
    • 嚢内血流阻害因子
  • 疾患病理別
    • 虚血性脳卒中
    • 脳動脈瘤
    • 頸動脈狭窄症
    • 動静脈奇形および瘻孔
    • その他の病気
  • エンドユーザー別
    • 病院
    • 外来手術センター
    • 専門クリニック
    • その他
  • 地域
    • 北東部
    • 南西部
    • 西部
    • 南東部
    • 中西部
  • 市場シェア（％）企業別、2024年

第5章 市場マッピング、2024年

• 製品別
• 疾患病理別
• エンドユーザー別
• 地域別

第6章 マクロ環境と産業構造

• 供給需要分析
• 輸入輸出分析
• バリューチェーン分析
• 神経血管塞栓装置市場のPESTEL分析
  • 政治的要因
  • 経済システム
  • 社会的影響
  • 技術の進歩
  • 環境への影響
  • 法令遵守と規制ポリシー（法定機関を含む）
• ポーターのファイブフォース分析
  • サプライヤーの力
  • 買い手の力
  • 代替の脅威
  • 新規参入の脅威
  • 競争企業間の敵対関係

第7章 市場力学

• 成長促進要因
• 成長抑制要因

第8章 規制枠組みとイノベーション

• 臨床試験
• 特許情勢
• FDA承認
• 製品イノベーション/新興技術

第9章 ケーススタディ

第10章 価格分析

第11章 主要企業の情勢

• 市場リーダー上位5社の競合マトリックス
• 上位5つの市場リーダーの市場収益分析（%、2024年）
• 合併および買収/合弁事業（該当する場合）
• SWOT分析（市場企業5社向け）

第12章 主要企業の展望

• Microport Scientific Corporation
• 会社概要
• 主要経営陣
• 製品とサービス
• 財務状況（報告通り）
• 主要市場への注力と地理的プレゼンス
• 最近の動向
• Integra LifeSciences Corporation
• Medtronic Plc
• Terumo Corporation（MicroVention, Inc）
• B. Braun Melsungen AG
• Penumbra, Inc
• Stryker Corporation
• Kaneka Medical Products
• Johnson &Johnson（Cerenovous）
• Codman &Shrutleff, Inc.

上記の企業は市場シェアに基づいて注文を保留しておらず、調査作業中に入手可能な情報に応じて変更される可能性があります。

第14章 戦略的提言

第15章 調査会社について・免責事項

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. United States Neurovascular Embolization Devices Market, By Value, In USD Million, 2018 - 2032F
• Figure 2. United States Neurovascular Embolization Devices Market, By Volume, In Thousand Units, 2018 - 2032F
• Figure 3. United States Neurovascular Embolization Devices Market Share, By Product, In USD Million, 2018 - 2032F
• Figure 4. United States Neurovascular Embolization Devices Market Share, By Product, In Thousand Units, 2018 - 2032F
• Figure 5. United States Neurovascular Embolization Devices Market Share, By Disease Pathology, In USD Million, 2018 - 2032F
• Figure 6. United States Neurovascular Embolization Devices Market Share, By Disease Pathology, In Thousand Units, 2018 - 2032F
• Figure 7. United States Neurovascular Embolization Devices Market Share, By End User, In USD Million, 2018 - 2032F
• Figure 8. United States Neurovascular Embolization Devices Market Share, By End User, In Thousand Units, 2018 - 2032F
• Figure 9. United States Neurovascular Embolization Devices Market Share, By Region, In USD Million, 2018 - 2032F
• Figure 10. United States Neurovascular Embolization Devices Market Share, By Region, In Thousand Units, 2018 - 2032F
• Figure 11. By Product Map-Market Size (USD Million) & Growth Rate (%), 2024
• Figure 12. By Disease Pathology Map-Market Size (USD Million) & Growth Rate (%), 2024
• Figure 13. By End User Map-Market Size (USD Million) & Growth Rate (%), 2024
• Figure 14. By Region Map-Market Size (USD Million) & Growth Rate (%), 2024

Improved access to healthcare services and insurance coverage in the United States have resulted in a more robust infrastructure for treatment of neurovascular patients. The United States Neurovascular Embolization Devices market was valued at 386.20 million in 2024 and is projected to be growing at a CAGR of 8.51% from 2025 to 2032. The increasing prevalence of hemorrhages & anomalies in cerebral arteries, rising cases of brain aneurysms, and arteriovenous malformations (AVMs) due to sedentary lifestyles are the main causes of surge in demand for neurovascular embolization devices. In addition, factors driving the growth of the United States neurovascular embolization devices market includes increasing geriatric population, increasing number of patients with hypertension and the introduction of novel neurovascular embolization devices.

An intravascular implant called a neurovascular embolization device is designed to permanently cut off blood supply to brain aneurysms and arteriovenous malformations.

Increasing Number of Patients with Cerebral Aneurysm Driving the Market

In recent years, there has been an increasing number of cerebral aneurysm patients in the United States, which has led to a growing demand for neurovascular embolization devices in the market. The market for these devices has been growing as more patients are diagnosed with cerebral aneurysms and seek treatment. Ruptured brain aneurysm affects around 6.7 million people in the United States, or one in every fifty people. Women above the age 55, have a higher risk of cerebral aneurysm rupture as compared to men.

Technological Advancements Accelerating the Market Growth

Technological advancements have made it possible to identify a size and shape of aneurysm. One major advancement is the development of new materials for embolization coils and flow diverters. These devices are used to block blood flow to abnormal blood vessels in the brain, and the new materials provide better visibility and control during the procedure. Additionally, there has been increased use of robotic systems for neurovascular procedures, which provide greater precision and control during the procedure.

Increasing Research Activities Support Market Expansion

The continuous emphasis on research activities has resulted in the creation of more sophisticated embolization devices, such as flow-diverting stents and liquid embolics, that have made the treatment of aneurysms and arteriovenous malformations more accessible. This improves the outcomes of the patients and enhances the success rate of neurovascular interventions. Increased investments in research enables a higher number of clinical trials and thus accelerates the regulatory approval process for new devices. Additionally, by focusing on research activities, medical technology companies are also able to ensure the development and availability of advanced technologies for effective management and treatment of chronic conditions.

For instance, in January 2023, Fluidx Medical Technology, Inc. release findings from their in vivo research for the Impass embolic device for middle meningeal artery (MMA) embolization for treating chronic subdural hematomas on the brain's surface. The device utilizes a low-viscosity, aqueous-based solution that solidifies into a durable embolus upon delivery. This technology aims to improve safety and efficacy during embolization procedures, potentially leading to better patient outcomes and increased adoption by healthcare providers, thus, supporting the market's expansion.

Cerebral Embolization and Aneurysm Coiling Devices Account for Majority of Market Share

Cerebral embolization and aneurysm coiling devices led the neurovascular device market. More than 40% of the market was accounted for cerebral embolization and aneurysm coiling devices, which are widely used in the treatment of aneurysms and strokes. Rising healthcare costs, increased R&D spending, and rising frequency of neurological diseases such as brain aneurysms, stroke, and arteriovenous malformations (AVMs) are few factors driving the market expansion.

Impact of COVID-19 on the United States Neurovascular Embolization Devices Market

The pandemic had a significant impact on the United States Neurovascular Embolization Device Market. The market has witnessed a decline in growth due to the pandemic's impact on healthcare facilities' operations, as well as a reduction in demand for non-urgent medical procedures. Additionally, the disruption of supply chains caused by the pandemic has led to delays in the production and distribution of neurovascular embolization devices, further impacting the market's growth. The market bounced back to pre-pandemic levels after upliftment of lockdown.

Impact of Russia-Ukraine War on the United States Neurovascular Embolization Devices Market

The Russia-Ukraine war did not have a significant impact on the United States neurovascular embolization market. Although, the war disrupted the trade dynamics such as demand-supply, pricing variances, impact on import/export and trading activities between United States, Russia, and Ukraine. Economic sanctions imposed by United States impacted the export of devices to Russia.

Key Players Landscape and Outlook

The market for neurovascular devices is competitive and is dominated by major players. The key players in the market are Terumo Corporation, Johnson & Johnson, and Medtronic Plc, Microport Scientific Corporation, Integra Life Sciences Corporation, Penumbra Inc and many others.

In 2021, Medtronic recalled two of its transcatheter devices intended to seal brain aneurysms: the Pipeline Flex Embolization Device and the Pipeline Flex Embolization Device with Shield Technology. The wire and tubes fractured and broke down when the delivery systems were used to place, remove, or relocate the stent within a patient.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. United States Neurovascular Embolization Devices Market Outlook, 2018-2032F

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2. Market Share & Forecast
  • 4.2.1. By Product
    • 4.2.1.1. Aneurysm Clips
    • 4.2.1.2. Liquid Embolic Systems
    • 4.2.1.3. Embolization Coils
    • 4.2.1.4. Flow Diversion Stents
    • 4.2.1.5. Intrasaccular Flow Disruptors
  • 4.2.2. By Disease Pathology
    • 4.2.2.1. Ischemic Strokes
    • 4.2.2.2. Cerebral Aneurysm
    • 4.2.2.3. Carotid Artery Stenosis
    • 4.2.2.4. Arteriovenous Malformations and fistulas
    • 4.2.2.5. Other Diseases
  • 4.2.3. By End User
    • 4.2.3.1. Hospitals
    • 4.2.3.2. Ambulatory Surgical Centers
    • 4.2.3.3. Specialty Clinics
    • 4.2.3.4. Others
  • 4.2.4. Region
    • 4.2.4.1. Northeast
    • 4.2.4.2. Southwest
    • 4.2.4.3. West
    • 4.2.4.4. Southeast
    • 4.2.4.5. Midwest
  • 4.2.5. By Company Market Share (%), 2024

5. Market Mapping, 2024

• 5.1. By Product
• 5.2. By Disease Pathology
• 5.3. By End User
• 5.4. By Region

6. Macro Environment and Industry Structure

• 6.1. Supply Demand Analysis
• 6.2. Import Export Analysis
• 6.3. Value Chain Analysis
• 6.4. PESTEL Analysis of the Neurovascular Embolization Devices Market
  • 6.4.1. Political Factors
  • 6.4.2. Economic System
  • 6.4.3. Social Implications
  • 6.4.4. Technological Advancements
  • 6.4.5. Environmental Impacts
  • 6.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 6.5. Porter's Five Forces Analysis
  • 6.5.1. Supplier Power
  • 6.5.2. Buyer Power
  • 6.5.3. Substitution Threat
  • 6.5.4. Threat from New Entrant
  • 6.5.5. Competitive Rivalry

7. Market Dynamics

• 7.1. Growth Drivers
• 7.2. Growth Inhibitors

8. Regulatory Framework and Innovation

• 8.1. Clinical Trials
• 8.2. Patent Landscape
• 8.3. FDA Approvals
• 8.4. Product Innovations/Emerging Technologies

9. Case Studies

10. Pricing Analysis

11. Key Players Landscape

• 11.1. Competition Matrix of Top Five Market Leaders
• 11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2024)
• 11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
• 11.4. SWOT Analysis (For Five Market Players)

12. Key Players Outlook

• 12.1. Microport Scientific Corporation
  • 12.1.1. Company Details
  • 12.1.2. Key Management Personnel
  • 12.1.3. Products & Services
  • 12.1.4. Financials (As reported)
  • 12.1.5. Key Market Focus & Geographical Presence
  • 12.1.6. Recent Developments
• 12.2. Integra LifeSciences Corporation
• 12.3. Medtronic Plc
• 12.4. Terumo Corporation (MicroVention, Inc)
• 12.5. B. Braun Melsungen AG
• 12.6. Penumbra, Inc
• 12.7. Stryker Corporation
• 12.8. Kaneka Medical Products
• 12.9. Johnson & Johnson (Cerenovous)
• 12.10. Codman & Shrutleff, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14. Strategic Recommendations

15. About Us & Disclaimer